All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How efficacious is CAR-T in childhood AML?
Bookmark this article
During the 2021 ASCO Annual Meeting, the AML Hub spoke with Hui Zhang, Guangzhou Women and Children's Medical Center, Guangzhou, CN. We asked, How efficacious is CAR-T in childhood AML?
How efficacious is CAR-T in childhood AML?
Zhang begins by outlining novel approaches to improve prognosis in relapsed/refractory patients, highlighting the increasing role of CAR T-cell therapy in pediatric AML. He then describes the encouraging results and response rates of his project, presented at ASCO. Finally, Zhang discusses which patients might benefit from CAR T-cell therapy, such as those who are unresponsive to tyrosine kinase inhibitors (TKIs).
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox